ALK and Nijmegen breakage syndrome: Following the discovery of ALK activating mutations in ∼8% of NBs, ALK has emerged as a tractable molecular target to counteract NB progression and several therapies aimed at inhibiting its tyrosine-kinase activity have been developed [249].